Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548860 | 0.78 | BACE1 (0.37) | ALDH1A1HTTKMT2A | |
| SCHEMBL3586527 | 0.77 | RIPK1 (0.31) | — | |
| SCHEMBL17748901 | 0.77 | CCR3 (0.53) | CCR3CCR5CHRM2MEN1LMNA | |
| SCHEMBL4951736 | 0.76 | MAOB (0.46) | MEN1KMT2A | |
| SCHEMBL18322450 | 0.75 | RIPK1 (0.34) | — | |
| SCHEMBL1810381 | 0.75 | NR1H2 (0.33) | LMNA | |
| SCHEMBL23724093 | 0.75 | CCR5 (0.40) | CCR5MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL8536867 | 0.75 | CCR5 (0.40) | CCR5CHRM2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3397755 | 0.74 | LIPG (0.39) | CCR3MEN1ALDH1A1LMNAHTT | |
| SCHEMBL21381104 | 0.74 | MAPT (0.41) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | CCR3 4504/4885CCR5 3284/4885CHRM2 4873/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | CCR3 4504/4885CCR5 3284/4885CHRM2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.